Update on rifampin, rifabutin, and rifapentine drug interactions

被引:129
作者
Baciewicz, Anne M. [1 ]
Chrisman, Cary R. [2 ]
Finch, Christopher K. [3 ]
Self, Timothy H. [3 ]
机构
[1] VA Puget Sound Hlth Care Ctr, Seattle, WA USA
[2] Methodist Med Ctr Oak Ridge, Oak Ridge, TN USA
[3] Univ Tennessee, Methodist Univ Hosp, Hlth Sci Ctr, Memphis, TN 38163 USA
关键词
Drug interactions; Rifabutin; Rifampin; Rifapentine; PLASMA-CONCENTRATIONS; TRANSPORTER INHIBITION; PLATELET-AGGREGATION; HEALTHY-VOLUNTEERS; ENZYME-INDUCTION; SINGLE-BLIND; PHARMACOKINETICS; ATORVASTATIN; CLOPIDOGREL; METABOLISM;
D O I
10.1185/03007995.2012.747952
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Rifampin is a potent inducer of both cytochrome P-450 oxidative enzymes and the P-glycoprotein transport system. Among numerous well documented, clinically significant interactions, examples include warfarin, oral contraceptives, itraconazole, digoxin, verapamil, simvastatin, and human immunodeficiency virus-related protease inhibitors. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. Rifapentine is also an inducer of drug metabolism. Methods: A literature search of English language journals from 2008 to March 2012 was completed using several databases, including PubMed, EMBASE, and SCOPUS. Search terms included rifampin, rifabutin, rifapentine AND drug interactions. Findings: Examples of clinically relevant interactions with rifampin demonstrated by recent reports include posaconazole, voriconazole, oxycodone, risperidone, mirodenafil, and ebastine. Conclusions: To avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin, rifabutin, or rifapentine are added to or discontinued from medication regimens, clinicians need to be aware of these interactions. Recent studies have indicated that other transporter systems play a role in these drug interactions. As reports of rifampin drug interactions continue to grow, this review is a reminder to clinicians to be vigilant.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 64 条
[31]   Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance [J].
Lau, WC ;
Gurbel, PA ;
Watkins, PB ;
Neer, CJ ;
Hopp, AS ;
Carville, DGM ;
Guyer, KE ;
Tait, AR ;
Bates, ER .
CIRCULATION, 2004, 109 (02) :166-171
[32]   Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers [J].
Lau, Y. Y. ;
Huang, Y. ;
Frassetto, L. ;
Benet, L. Z. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (02) :194-204
[33]   Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin [J].
Li, AP ;
Reith, MK ;
Rasmussen, A ;
Gorski, JC ;
Hall, SD ;
Xu, L ;
Kaminski, DL ;
Cheng, LK .
CHEMICO-BIOLOGICAL INTERACTIONS, 1997, 107 (1-2) :17-30
[34]   Effect of rifampicin on the pharmacokinetics of atenolol [J].
Lilja, Jari J. ;
Juntti-Patinen, Laura ;
Neuvonen, Pertti J. .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 98 (06) :555-558
[35]   Cytochrome P4502B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity [J].
Loboz, Katarzyna K. ;
Gross, Annette S. ;
Williams, Kenneth M. ;
Liauw, Winston S. ;
Day, Richard O. ;
Blievernicht, Julia K. ;
Zanger, Ulrich M. ;
McLachlan, Andrew J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (01) :75-84
[36]   Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers [J].
Mahatthanatrakul, W. ;
Nontaput, T. ;
Ridtitid, W. ;
Wongnawa, M. ;
Sunbhanich, M. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2007, 32 (02) :161-167
[37]   Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole [J].
Martin P. ;
Oliver S. ;
Robertson J. ;
Kennedy S.-J. ;
Read J. ;
Duvauchelle T. .
Drugs in R & D, 2011, 11 (1) :37-51
[38]   Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients [J].
McCance-Katz, Elinore F. ;
Moody, David E. ;
Prathikanti, Sudha ;
Friedland, Gerald ;
Rainey, Petrie M. .
DRUG AND ALCOHOL DEPENDENCE, 2011, 118 (2-3) :326-334
[39]   Overcoming the effect of rifampin on the tacrolimus metabolism by itraconazole administration in an allogeneic hematopoietic stem cell transplant recipient [J].
Mori, Takehiko ;
Aisa, Yoshinobu ;
Kato, Jun ;
Nakamura, Yukinori ;
Shimizu, Takayuki ;
Okamoto, Shinichiro .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 91 (03) :553-554
[40]   Failure of pain control using transdermal fentanyl during rifampicin treatment [J].
Morii, Hiroaki ;
Chiba, Mikio ;
Konishi, Hiroki ;
Endo, Yoshihiro ;
Yamaji, Akira .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2007, 33 (01) :5-6